Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The main goal of PD research is to develop disease-modifying drugs to delay or prevent the
underlying neurodegenerative process. Levodopa, as the gold standard for PD treatment, is
associated with the occurrence of motor complications. Many previous studies have confirmed
that Stalevo can reduce the side effects of levodopa alone. Moreover, the effects of Stalevo
on the treatment of PD patients have been extensively studied, but the efficacy of Stalevo in
early PD patients has been less studied. Therefore, it is necessary to further study the
treatment of early PD with Stalevo, and observe whether increasing the number of medication
can reduce the occurrence of dyskinesis. The research results will help to deepen the
understanding of Stalevo in the treatment of early PD and its clinical efficacy.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University